Novo Nordisk Pharma (Taiwan) Ltd.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Healthcare Asia Pharma Awards 2023 Winner: Novo Nordisk Pharma (Taiwan) Ltd.
Healthcare Asia Pharma Awards 2023 Winner: Novo Nordisk Pharma (Taiwan) Ltd.
Novo Nordisk Pharma (Taiwan) Ltd. wins the ESG Programme of the Year - Taiwan award at the Healthcare Asia Pharma Awards 2023.
Novo Nordisk Pharma Taiwan awarded ESG Program of the Year - Taiwan by the Healthcare Asia Pharma Awards
The company's Corporate Social Responsibility awareness programme aims to give back to local communities and take action for environmental improvement.
Most Read
1. Asian medical device markets face cost shocks amidst Iran conflict 2. Gene and cell therapy boom drives DNA manufacturing market toward $21.82B by 2034 3. HSA to expand role in accelerating biomedical sector growth: Ong Ye Kung 4. How do rising claims drive healthcare investment strategy? 5. Global dental articulators market to reach $227.8m by 2030Resource Center
Read Here
Advertise
Sign Up
Events
Event News
He discusses how healthcare systems in Asia Pacific need to evolve beyond simply expanding coverage and towards delivering equitable, sustainable, and high-impact care.
Commentary
Beyond ChatGPT: The rise of multimodal AI assistants in clinical settings
2026 biotech playbook: Hong Kong at the centre of China’s globalisation